Related Experiment Video
Updated: Jun 19, 2026
05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
New therapies for diabesity
1Life and Health Sciences, Aston University, Aston Street, Aston Triangle, Birmingham B4 7ET, UK. c.j.bailey@aston.ac.uk
Current Diabetes Reports
|October 2, 2009
Summary
Managing type 2 diabetes with obesity requires complex treatments. New medications, including GLP-1 agonists and SGLT2 inhibitors, offer improved insulin secretion, weight loss, and reduced hypoglycemia risks.
Area of Science:
- Endocrinology
- Metabolic Diseases
- Pharmacology
Background:
- Type 2 diabetes often coexists with obesity, termed 'diabesity,' presenting significant therapeutic challenges.
- Current treatment paradigms frequently necessitate multiple, differently acting agents, driving the need for combination therapies.
Purpose of the Study:
- To review emerging therapeutic agents for managing type 2 diabetes and obesity.
- To highlight novel pharmacological approaches offering improved efficacy and safety profiles.
Main Methods:
- Review of current clinical development pipelines for antidiabetic and antiobesity agents.
- Analysis of mechanisms of action for novel drug classes.
Main Results:
- Longer-acting glucagon-like peptide-1 (GLP-1) agonists show promise for insulin stimulation, weight loss, and low hypoglycemia risk.
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors provide a new route for hyperglycemia reduction and weight management via urinary glucose excretion.
- Dipeptidyl peptidase-4 (DPP-4) inhibitors and selective peroxisome proliferator-activated receptor (PPAR) modulators are also under investigation.
Conclusions:
- Advancements in pharmacotherapy are providing more options for treating diabesity.
- Emerging agents like GLP-1 agonists and SGLT2 inhibitors offer dual benefits of glycemic control and weight reduction.
- Continued research into agents with combined antidiabetic and antiobesity activity is crucial for complex patient management.
Related Concept Videos
01:15Diabetes: Management and Pharmacotherapy
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:26Type I Diabetes II: Pathophysiology
Type 1 diabetes mellitus arises from an immune-mediated destruction of pancreatic β-cells, resulting in an absolute deficiency of insulin. This process develops in genetically susceptible individuals when autoimmunity, environmental exposures, and immunologic dysregulation converge to trigger a targeted attack on the insulin-producing cells of the pancreas. The β-cells are located within the islets of Langerhans and are essential for regulating blood glucose by facilitating cellular uptake of...